Company Summary
Search
Home Page
 
iCo Therapeutics Inc. 
Listed Company 
Current   Past  
Fiscal Year EndCompany StatusExempt Flag
December 31TradingN
Board of Directors
NamePosition
Andrew Rae  President
  Director of the Board
Douglas Janzen  Director of the Board
Noel Hall  Director of the Board
Richard Barker  Director of the Board
William Jarosz  Director of the Board
Incorporation Locations
Inc. DateExpiry DateCountryRegionDescription
15/Feb/2005  Canada British Columbia Business Corporations Act 
Exchange Filing Office
Location
Vancouver Regional Service Office
Business Type(s)
Primary/SecondaryBusiness TypeDetails
Primary  Research and Development of Pharmaceutical Products  News Release June 30, 2014-iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. 
Securities
SymbolSecurity NameMarketStatus
ICOiCo Therapeutics IncTSX VentureTRADING
Name HistoryFromTo
iCo Therapeutics Inc.7/Jan/2008Present
Company Facts Reconciliation
SubjectDate Returned
Fall 2014 CFRNot Received
Associations
Auditing Firm:  Price Waterhouse Coopers LLP
Investor Relations:  Michael Moore
Law Firm:  McCarthy Tetrault LLP
Sponsor:  Canaccord Capital Corp.
Transfer Agent:  Computershare Investor Services Inc.
Latest Information
TypeDateTitle
News Releases  28/Nov/2014  NEWS RELEASE - ICO THERAPEUTICS ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS AND CORPORATE UPDATE[CANADA NEWSWIRE]
    NEWS RELEASE - IMMUNE ANNOUNCES PRICING OF PUBLIC OFFERING OF C[MARKET NEWS]
    NEWS RELEASE - ICO THERAPEUTICS ANNOUNCES ORAL AMPHOTERICIN PRESENTATIONS AT AAPS[CANADA NEWSWIRE]
Bulletins  28/Jan/2014  Prospectus-Share Offering
Meetings and Public Filings  Information on financial statements, public filings and corporate meetings for all Canadian public companies can be found at www.sedar.com
Property Locations
(not available)

* Historical Data